Acts on dihydrofolate synthase, interfering with the first step of folic acid synthesis, and has a synergistic antibacterial effect when used in combination with trimethoprim

It acts on the second step of folic acid anabolism, selectively inhibits the action of dihydrofolate reductase, and has a synergistic antibacterial effect when used in combination with sulfadiazine

Unspecified

This product is a nitroimidazole derivative that can inhibit the redox reaction of amoeba and break the nitrogen chain of the protozoa. In vitro tests have shown that when the drug concentration is 1-2 mg/L, the histolytica amoeba can undergo morphological changes in 6-20 hours and all are killed within 24 hours. At a concentration of 0.2 mg/L, the histolytica amoeba can be killed within 72 hours. This product has a strong effect of killing trichomonas, and its mechanism is unknown. Metronidazole has a killing effect on anaerobic microorganisms, and the metabolites generated when it is reduced in the human body also have anti-anaerobic effects, inhibiting the synthesis of bacterial deoxyribonucleic acid, thereby interfering with the growth and reproduction of bacteria, and ultimately causing bacterial death.

This product is a nitroimidazole derivative that can inhibit the redox reaction of amoeba target=_blank and break the nitrogen chain of the protozoa. In vitro tests have shown that when the drug concentration is 1-2 mg/L, the histolytica amoeba can undergo morphological changes in 6-20 hours and all are killed within 24 hours. At a concentration of 0.2 mg/L, the histolytica amoeba can be killed within 72 hours. This product has a strong effect of killing trichomonas, and its mechanism is unknown. Metronidazole has a killing effect on anaerobic microorganisms, and the metabolites generated when it is reduced in the human body also have anti-anaerobic effects, inhibiting the synthesis of bacterial deoxyribonucleic acid, thereby interfering with the growth and reproduction of bacteria, and ultimately causing bacterial death.

Anticonvulsant, antiepileptic, anti-neuropathic pain, anti-manic-depressive, improves the symptoms of certain mental illnesses, and treats central diabetes insipidus; the mechanism may include use-dependent blocking of various excitable cell membrane Na channels, inhibition of T-type calcium channels, enhancement of central noradrenergic nerve activity, promotion of antidiuretic hormone (ADH) secretion, or increased sensitivity of effectors to ADH.

This product has a broad-spectrum antimicrobial effect in vitro, including aerobic Gram-negative and Gram-positive bacteria, anaerobes, Rickettsia, spirochetes and Chlamydia. It has bactericidal effects on Haemophilus influenzae, Streptococcus pneumoniae and Neisseria meningitidis; it only has antibacterial effects on anaerobic bacteria such as Staphylococcus aureus, Streptococcus pyogenes, Streptococcus viridans, Group B hemolytic Streptococcus, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Salmonella typhi, Salmonella paratyphi, Shigella, Bacteroides fragilis, etc. Pseudomonas aeruginosa, Acinetobacter, Enterobacter, Serratia marcescens, indole-positive Proteus, methicillin-resistant Staphylococcus and Enterococcus are usually resistant to chloramphenicol. Chloramphenicol is fat-soluble, enters bacterial cells by diffusion, and reversibly binds to the 50S subunit of bacterial ribosomes, inhibiting the formation of peptide chains, thereby preventing protein synthesis.